RHNM.F Stock Overview
Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rhinomed Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.019 |
| 52 Week High | AU$0.07 |
| 52 Week Low | AU$0.004 |
| Beta | 0.88 |
| 1 Month Change | 0.53% |
| 3 Month Change | 29.25% |
| 1 Year Change | -70.29% |
| 3 Year Change | -77.91% |
| 5 Year Change | -82.73% |
| Change since IPO | -87.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| RHNM.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 2.3% | 1.6% |
| 1Y | -70.3% | 10.8% | 25.1% |
Return vs Industry: RHNM.F underperformed the US Pharmaceuticals industry which returned 20.4% over the past year.
Return vs Market: RHNM.F underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| RHNM.F volatility | |
|---|---|
| RHNM.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RHNM.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine RHNM.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | Michael Johnson | www.rhinomed.global |
Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. The company offers wearable nasal technology that improve breathing, sleeping, and maintaining health and diagnose disease. Its products include Turbine for enhanced breathing in sports; Mute, which helps to breath more and snore less; Pronto, a vapor inhaler to improve airflow and better sleep; and Rhinoswab that is used to collect a nasal swab.
Rhinomed Limited Fundamentals Summary
| RHNM.F fundamental statistics | |
|---|---|
| Market cap | US$7.52m |
| Earnings (TTM) | -US$7.13m |
| Revenue (TTM) | US$5.26m |
1.4x
P/S Ratio-1.1x
P/E RatioIs RHNM.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RHNM.F income statement (TTM) | |
|---|---|
| Revenue | AU$8.05m |
| Cost of Revenue | AU$2.78m |
| Gross Profit | AU$5.28m |
| Other Expenses | AU$16.18m |
| Earnings | -AU$10.91m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.038 |
| Gross Margin | 65.53% |
| Net Profit Margin | -135.49% |
| Debt/Equity Ratio | -90.4% |
How did RHNM.F perform over the long term?
See historical performance and comparison